Recent 8-K filings for ENVB

• May 29, 2026, 4:13 PM ET other material materiality 0.65 neutral item 5.02item 5.07item 9.01

  Enveric shareholders approve reverse stock split, reject increase in authorized shares

  Reverse stock split (1:5 to 1:15) approved: 793,344 for, 190,175 against, 8,309 abstentions.

• May 15, 2026, 8:00 AM ET earnings materiality 0.70 positive item 2.02item 9.01

  Enveric Biosciences Q1 net loss narrows to $1.6M; cash position improved to $10.3M

  Net loss $1.6M ($1.08 loss per share) vs $2.2M ($14.58) in Q1 2025; cash $4.9M at March 31.

• April 20, 2026, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements ×3

  Enveric closes $5M private placement of shares and warrants with potential $8.9M additional proceeds

  Gross proceeds of ~$5M from sale of 2.22M shares/pre-funded warrants; potential $8.9M more if warrants exercised.

• March 27, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Enveric Biosciences reports Q4 2025 net loss of $4.0M, cash $4.7M, advances EB-003 towards IND

  Net loss of $4.0M in Q4 2025 ($6.12 per share) vs $3.2M loss ($58.06 per share) in Q4 2024; per-share impacted by 1:12 reverse split.

• December 12, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  Enveric Biosciences raises $3.1M via warrant exercise inducement at $7.05 per share

  Gross proceeds of ~$3.1M from cash exercise of 426,390 existing warrants at reduced price of $7.05/sh.

• December 11, 2025, 6:59 PM ET other material materiality 0.80 negative item 5.07item 9.01

  Enveric shareholders approve 50x increase in authorized shares and reverse split authority

  Approved increase in authorized common shares from 100M to 5B (50x) at board discretion.

• November 14, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Enveric Biosciences Q3 net loss $3.4M, cash $3.8M; EB-003 advances toward IND 2026

  Net loss of $3.4M ($10.81 per share) in Q3 2025 vs $2.1M ($43.10) in Q3 2024; cash $3.8M as of Sept 30, 2025.

• October 23, 2025, 7:59 PM ET other material materiality 0.85 negative item 3.01item 3.03item 5.03item 8.01item 9.01 ◈ Listing & Compliance Notices◈ Governance Changes

  Enveric Biosciences announces 1-for-12 reverse stock split to address Nasdaq bid-price deficiency

  Reverse split effective 8:00 a.m. ET on October 28, 2025; shares outstanding to drop from 6,219,568 to ~518,297.

• September 18, 2025, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 3.02item 9.01

  Enveric raises $2.2M in warrant exercise inducement; issues new Series C/D warrants

  Holders exercised 1,212,499 Series A and 1,212,499 Series B warrants at reduced price of $0.915/share.

• August 29, 2025, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Enveric Biosciences receives Nasdaq deficiency notice for failing minimum equity requirement

  Nasdaq notified Enveric on Aug 26, 2025 that stockholders' equity of $2.18M as of June 30, 2025 is below $2.5M minimum.

• August 14, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Enveric Biosciences Q2 net loss $2.5M; EB-003 dual mechanism disclosed, IND on track for early 2026

  Net loss $2.5M ($0.97/shr) vs $1.9M ($3.72/shr) in Q2 2024; cash $2.8M at June 30.

• June 3, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07item 9.01

  Enveric stockholders approve conditional reverse stock split to avoid Nasdaq delisting

  Stockholders authorized board to implement reverse stock split between 1:5 and 1:50 if Nasdaq issues bid price delisting determination before Jan 28, 2026.

• April 14, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01item 9.01

  Enveric Biosciences dismisses Marcum LLP, engages CBIZ CPAs as new auditor effective April 14

  Marcum LLP dismissed as independent auditor; CBIZ CPAs P.C. engaged effective April 14, 2025 for FY 2025.

• March 31, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Enveric Biosciences Q4 2024 net loss $3.2M, cash $2.2M; out-licenses up to $144M

  Net loss $3.2M for Q4 2024; diluted EPS loss $4.83; cash-on-hand $2.2M.

• March 6, 2025, 6:59 PM ET regulatory materiality 0.60 positive item 8.01

  Enveric Biosciences regains Nasdaq bid price compliance

  Received notice from Nasdaq on March 4, 2025 that it complied with Listing Rule 5550(a)(2).

• January 21, 2025, 6:59 PM ET other material materiality 0.60 neutral item 3.03item 5.03item 5.07item 9.01

  Enveric Biosciences announces 1-for-15 reverse stock split effective Jan 27, 2025

  Shareholders approved reverse split at a special meeting on Jan 17, 2025; ratio range 1:10 to 1:100.

• November 22, 2024, 6:59 PM ET regulatory materiality 0.80 negative item 3.01

  Enveric Biosciences receives Nasdaq delisting notice on Nov 20 for bid price failure

  Nasdaq notified Enveric on Nov 20, 2024, that it failed to meet the $1.00 minimum bid price requirement by the Nov 12 compliance deadline.

• November 12, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01

  Enveric out-licenses EB-002 to MycoMedica for up to $62M milestones plus royalties

  Exclusive global license for EB-002 (EVM201) to treat neuropsychiatric disorders.

• August 12, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Enveric Biosciences reports Q2 2024 net loss of $1.7M; prioritizes EB-003 as lead candidate

  Net loss of $1.7M ($0.23/share) vs $6.4M loss in Q2 2023; cash on hand $3.5M.

• May 17, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

  Enveric Biosciences receives Nasdaq delisting notice for bid price below $1.00

  Closing bid price below $1.00 for 30 consecutive business days as of May 16, 2024.

• March 26, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Enveric Biosciences reports Q4 2023 net loss of $3.44M; selects EB-003, signs out-licensing term sheets

  Net loss $3.44M ($1.46 per share) vs $8.80M ($4.89 per share) in Q4 2022.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.57 · Most common event other_material

8 positive 6 negative 28 neutral

source · ENVB on sec.gov